Sestak, Ivana, Cuzick, Jack, Sapunar, Francisco, Eastell, Richard, Forbes, John F., Bianco, Angelo R., Buzdar, Aman U.. Elsevier; 2008. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.

Davies, Christina, Pan, Hongchao, Bradbury, Joan, Clarke, Michael, Collins, Rory, Davis, Susan R., Delmestri, Antonella, Forbes, John F., Haddad, Peiman, Hou, Ming-Feng, Inbar, Moshe, Khaled, Hussein, Godwin, Jon, Kielanowska, Joanna, Kwan, Wing-Hong, Mathew, Beela S., Mittra, Indraneel, Mueller, Bettina, Nicolucci, Antonio, Peralta, Octavio, Pernas, Fany, Petruzelka, Lubos, Pienkowski, Tadeusz, Gray, Richard, Radhika, Ramachandran, Rajan, Balakrishnan, Rubach, Maryan T., Tort, Sera, Urrutia, Gerard, Valentini, Miriam, Wang, Yaochen, Peto, Richard, Arriagada, Rodrigo, Raina, Vinod, Abraham, Mirta, Medeiros Alencar, Victor Hugo, Badran, Atef, Bonfill, Xavier. The Lancet Publishing Group; 2013. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Sestak, Ivana, Singh, Shalini, Eastell, Richard, Cuzick, Jack, Blake, Glen M., Patel, Rajesh, Gossiel, Fatma, Coleman, Rob, Dowsett, Mitch, Forbes, John F., Howell, Anthony. The Lancet Publishing Group; 2014. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.

The BIG 1-98 Collaborative Group, Forbes, John F.. Massachusetts Medical Society; 2009. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

Cuzick, Jack, Sestak, Ivana, Bonanni, Bernardo, Palva, Tina, Howell, Anthony, Forbes, John F., Dowsett, Mitch, Knox, Jill, Cawthorn, Simon, Saunders, Christobel, Roche, Nicola, Mansel, Robert E., von Minckwitz, Gunter. Lancet Publishing Group; 2014. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

Avery-Kiejda, Kelly A., Braye, Stephen G., Mathe, Andrea, Forbes, John F., Scott, Rodney J.. BioMed Central; 2014. Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer.

Sestak, Ivana, Harvie, Michelle, Howell, Anthony, Forbes, John F., Dowsett, Mitch, Cuzick, Jack. Springer; 2012. Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.

Cuzick, Jack, Sestak, Ivana, Baum, Michael, Buzdar, Aman, Howell, Anthony, Dowsett, Mitch, Forbes, John F.. The Lancet Publishing Group; 2010. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Pundavela, Jay, Roselli, Severine, Hondermarck, Hubert, Faulkner, Sam, Attia, John, Scott, Rodney J., Thorne, Rick F., Forbes, John F., Bradshaw, Ralph A., Walker, Marjorie M., Jobling, Phillip. John Wiley & Sons; 2015. Nerve fibers infiltrate the tumor microenvironment and are associated with nerve growth factor production and lymph node invasion in breast cancer.

Avery-Kiejda, Kelly A., Braye, Stephen G., Forbes, John F., Scott, Rodney J.. BioMed Central; 2014. The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer.

Leyland-Jones, Brian R., Ambrosone, Christine B., Abramovitz, Mark, Braga, Sofia, Cardoso, Fatima, Harbeck, Nadia, Denkert, Carsten, Jewell, Scott D., Bartlett, John, Ellis, Matthew J. C., Enos, Rebecca A., Raji, Adekunle, Pins, Michael R., Zujewski, Jo Anne, Hewitt, Stephen M., Forbes, John F.. American Society of Clinical Oncology; 2008. Recommendations for collection and handling of specimens from group breast cancer clinical trials.

Lombard, Janine M., Zdenkowski, Nicholas, Wells, Kathy, Beckmore, Corinna, Reaby, Linda, Forbes, John F., Chirgwin, Jacquie. Springer Berlin Heidelberg; 2016. Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options.

Mathe, Andrea, Wong-Brown, Michelle, Morten, Brianna, Forbes, John F., Braye, Stephen G., Avery-Kiejda, Kelly A., Scott, Rodney J.. Nature Publishing Group; 2015. Novel genes associated with lymph node metastasis in triple negative breast cancer.

Goldhirsch, A., Winer, E. P., Bonnefoi, Hervé, Bretel-Morales, Denisse, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Colleoni, Marco, Costa, Alberto, Curigliano, Giuseppe, Davidson, Nancy E., Leo, Angelo Di, Coates, A. S., Ejlertsen, Bent, Forbes, John F., Gelber, Richard D., Gnat, Michael, Goldhirsch, Aron, Goodwin, Pamela, Goss, Paul E., Harris, Jay R., Hayes, Daniel F., Hudis, Clifford A., Gelber, R. D., Ingle, James N., Jassem, Jacek, Jiang, Zefei, Karlsson, Per, Loibl, Sibylle, Morrow, Monica, Namer, Moise, Osborne, C. Kent, Partridge , Ann H., Penault-Llorca, Fréderiqué, Piccart-Gebhart, M., Perou, Charles M., Piccart-Gebhart, Martine, Pritchard, Kathleen I., Rutgers, Emiel J. T., Sedlmayer, Felix, Semiglazov, Vladimir, Shao, Zhi-Ming, Smith, Ian, Thürlimann, Beat, Toi, Masakazu, , Tutt, Andrew, Untch, Michael, Viale, Giuseppe, Watanabe, Toru, Wilcken, Nicholas, Winer, Eric P., Wood, William C., Senn, H. - J., Albain, Kathy S., André, Fabrice, Bergh, Jonas. Oxford University Press; 2013. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013.

Coates, A. S., Winer, E. P., Bergh, Jonas, Bonnefoi, Hervé, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Colleoni, Marco, Curigliano, Giuseppe, Davidson, Nancy E., Leo, Angelo Di, Ejlertsen, Bent, Goldhirsch, A., Forbes, John F., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., André, Fabrice, Baselga, José. Oxford University Press; 2015. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015.

Crivellari, Diana, Sun, Zhuoxin, Gelber, Richard D., Colleoni, Marco, Lang, Istvan, Del Mastro, Lucia, Gladieff, Laurence, Rabaglio, Manuela, Smith, Ian E., Chirgwin, Jacquie H., Goldhirsch, Aron, Coates, Alan S., Price, Karen N., Thurlimann, Beat, Mouridsen, Henning, Mauriac, Louis, Forbes, John F., Paridaens, Robert J., Castiglione-Gertsch, Monica. American Society of Clinical Oncology; 2008. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

Cuzick, Jack, Warwick, Jane, Pinney, Elizabeth, Duffy, Stephen W., Cawthorn, Simon, Howell, Anthony, Forbes, John F., Warren, Ruth M. L.. Oxford University Press; 2011. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.

Sestak, Ivana, Distler, Wolfgang, Forbes, John F., Dowsett, Mitch, Howell, Anthony, Cuzick, Jack. American Society of Clinical Oncology; 2010. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.

Zdenkowski, Nicholas, Butow, Phyllis, Fewster, Sheryl, Beckmore, Corinna, Wells, Kathryn, Forbes, John F., Boyle, Frances. Wiley-Blackwell; 2016. Exploring decision-making about neo-adjuvant chemotherapy for breast cancer (letter).

Cuzick, Jack, Sestak, Ivana, Cawthorn, Simon, Hamed, Hisham, Holli, Kaija, Howell, Anthony, Forbes, John F.. Lancet Publishing Group; 2015. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.

Forbes, John F., Sestak, Ivana, Holcombe, Chris, Coleman, Robert E., Jones, Louise, Ellis, Ian, Cuzick, Jack, Howell, Anthony, Bonanni, Bernardo, Bundred, Nigel, Levy, Christelle, von Minckwitz, Gunter, Eiermann, Wolfgang, Neven, Patrick, Stierer, Michael. Elsevier; 2016. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial.

Toi, Masakazu, Winer, Eric P., Klimberg, V. Suzanne, Inamoto, Takashi, Benson, John R., Forbes, John F., Mitsumori, Michihide, Robertson, John F. R., Sasano, Hironobu, Von Minckwitz, Gunter, Yamauchi, Akira. Springer; 2011. Identifying gaps in the locoregional management of early breast cancer: highlights from the Kyoto Consensus Conference.

Ewertz, Marianne, Gray, Kathryn P., Gelber, Richard D., Colleoni, Marco, Láng, István, Smith, Ian E., Coates, Alan S., Goldhirsch, Aron, Mouridsen, Henning T., Regan, Meredith M., Ejlertsen, Bent, Price, Karen N., Thürlimann, Beat, Bonnefoi, Hervé, Forbes, John F., Paridaens, Robert J., Rabaglio, Manuela. American Society of Clinical Oncology; 2012. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial.

Smith, Samuel, Sestak, Ivana, Howell, Anthony, Forbes, John F., Cuzick, Jack. American Society of Clinical Oncology; 2017. Participant-reported symptoms and their effect on long-term adherence in the International Breast Cancer Intervention Study I (IBIS I).

Stirzaker, Clare, Zotenko, Elena, Avery-Kiejda, Kelly A., Peters, Kate M., French, Juliet D., Stein, Sandra, Korbie, Darren J., Trau, Matt, Forbes, John F., Scott, Rodney J., Brown, Melissa A., Francis, Glenn D., Song, Jenny Z., Clark, Susan J., Qu, Wenjia, Nair, Shalima S., Locke, Warwick J., Stone, Andrew, Armstong, Nicole J., Robinson, Mark D., Dobrovic, Alexander. Nature Publishing Group; 2015. Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value.

Colleoni, Marco, Giobbie-Hurder, Anita, Chirgwin, Jacquie, Pienkowski, Tadeusz, Wardley, Andrew, Price, Karen N., Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron, Regan, Meredith M., Thürlimann, Beat, Mouridsen, Henning, Mauriac, Louis, Forbes, John F., Paridaens, Robert, Láng, István, Smith, Ian. American Society of Clinical Oncology; 2011. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study.

Moore, Halle C. F., Unger, Joseph M., Partridge, Ann H., Dakhil, Shaker R., Garcia, Agustin A., Gralow, Julie, Lombard, Janine M., Forbes, John F., Martino, Silvana, Barlow, William E., Fabian, Carol J., Minasian, Lori, Phillips, Kelly-Anne, Meyskens, Frank L., Gelber, Richard D., Hortobagyi, Gabriel N., Albain, Kathy S., , Boyle, Frances, Hitre, Erika, Porter, David, Francis, Prudence A., Goldstein, Lori J., Gomez, Henry L., Vallejos, Carlos S.. Massachusetts Medical Society; 2015. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

Mathe, Andrea, Wong-Brown, Michelle, Locke, Warwick J., Stirzaker, Clare, Braye, Stephen G., Forbes, John F., Clark, Susan J., Avery-Kiejda, Kelly A., Scott, Rodney J.. Nature Publishing Group; 2016. DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients.

Phillips, Kelly-Anne, Regan, Meredith, Abdi, Ehtesham, Domchek, Susan, Feng, Yang, Price, Karen, Coates, Alan, Gelber, Richard, Maruff, Paul, Boyle, Frances, Forbes, John F., Ahles, Tim, Ribi, Karin, Fleming, Gini, Bernhard, Jürg, Francis, Prudence A., Puglisi, Fabio, Bellet, Meritxell, Spazzapan, Simon, Karlsson, Per, Budman, Daniel, Zaman, Khalil. Nature Publishing; 2016. Adjuvant ovarian function suppression and cognitive function in women with breast cancer.

Pagani, Olivia, Gelber, Shari, Thürlimann, Beat, Fey, Martin F., Murray, Elizabeth, Forbes, John F., Coates, Alan S., Goldhirsch, Aron, Simoncini, Edda, Castiglione-Gertsch, Monica, Price, Karen N., Gelber, Richard D., Holmberg, Stig B., Crivellari, Diana, Collins, John, Lindtner, Jurij. Springer; 2009. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.

Gao, Jinnan, Warren, Ruth, Warren-Forward, Helen, Forbes, John F.. Springer; 2008. Reproducibility of visual assessment on mammographic density.

Bliss, Judith M., Kilburn, Lucy S., van de Velde, Cornelius J. H., Lønning, Per. E., Morden, James, Reise, Justine, Cisar, Laura, Menschik, Thomas, Coombes, R. Charles, Coleman, Robert E., Forbes, John F., Coates, Alan S., Jones, Stephen E., Jassem, Jack, Delozier, Thierry, Andersen, Jørn, Paridaens, Robert. American Society of Clinical Oncology; 2012. Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study.

Spagnolo, Francesco, Sestak, Ivana, Howell, Anthony, Forbes, John F., Cuzick, Jack. American Society of Clinical Oncology; 2016. Anastrozole-induced carpal tunnel syndrome: results from the international breast cancer intervention study II prevention trial.

Cuzick, Jack, Sestak, Ivana, Forbes, John F., Dowsett, Mitch, Cawthorn, Simon, Mansel, Robert E., Loibl, Sibylle, Bonanni, Bernardo, Evans, D. Gareth, Howell, Anthony. The Lancet Publishing Group; 2020. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.

Ring, Alistair, Sestak, Ivana, Baum, Michael, Howell, Anthony, Buzdar, Aman, Dowsett, Mitch, Forbes, John F., Cuzick, Jack. American Society of Clinical Oncology; 2011. Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the arimidex, tamoxifen alone or in combination trial.

Thürlimann, Beat, Price, Karen N., Goldhirsch, Aron, Gelber, Richard D., Holmberg, Stig B., Crivellari, Diana, Colleoni, Marco, Collins, John, Forbes, John F., Castiglione-Gertsch, Monica, Coates, Alan S.. Springer; 2009. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93.

Cuzick, Jack, Sestak, Ivanka, Forbes, John F., Dowsett, Mitch, Cawthorn, Simon, Mansel, Robert E., Loibl, Sibylle, Bonanni, Bernardo, Evans, D. Gareth, Howell, Anthony. Lancet Publishing Group; 2020. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of randomised controlled trial.

Tang, Gong, Cuzick, Jack, Costantino, Joseph P., Dowsett, Mitch, Forbes, John F., Crager, Michael, Mamounas, Eleftherios P., Shak, Steven, Wolmark, Norman. American Society of Clinical Oncology; 2011. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.

Cuzick, Jack, Sestak, Ivana, Pinder, Sarah E., Ellis, Ian O., Forsyth, Sharon, Bundred, Nigel J., Forbes, John F., Bishop, Hugh, Fentiman, Ian S., George, William D.. The Lancet Publishing Group; 2011. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.

Dowsett, Mitch, Sestak, Ivana, Buus, Richard, Lopez-Knowles, Elena, Mallon, Elizabeth, Howell, Anthony, Forbes, John F., Buzdar, Aman, Cuzick, Jack. American Association for Cancer Research; 2015. Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer.

Bartlett, John M. S., Ahmed, Ikhlaaq, Brookes, Cassandra L., Forbes, John F., Viale, Giuseppe, Cuzick, Jack, Dowsett, Mitchell, Rea, Daniel W., Regan, Meredith M., Sestak, Ivana, Mallon, Elizabeth A., Dell'Orto, Patrizia, Thürlimann, Beat, Seynaeve, Caroline, Putter, Hein, Van de Velde, Cornelis J. H.. Elsevier; 2017. HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.

Cuzick, Jack, Dowsett, Mitch, Howell, Anthony, Buzdar, Aman U., Forbes, John F., Pineda, Silvia, Wale, Christopher, Salter, Janine, Quinn, Emma, Zabaglo, Lila, Mallon, Elizabeth, Green, Andrew R., Ellis, Ian O.. American Society of Clinical Oncology; 2011. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer.

Regan, Meredith M., Neven, Patrick, Rabaglio, Manuela, Price, Karen N., Gelber, Richard D., Coates, Alan S., Thürlimann, Beat, Giobbie-Hurder, Anita, Goldhirsch, Aron, Ejlertsen, Bent, Mauriac, Louis, Forbes, John F., Smith, Ian, Láng, István, Wardley, Andrew. Elsevier; 2011. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up.

Colleoni, Marco, Sun, Zhuoxin, Goldhirsch, Aron, Price, Karen N., Karlsson, Per, Forbes, John F., Thürlimann, Beat, Gianni, Lorenzo, Castiglione, Monica, Gelber, Richard D., Coates, Alan S.. American Society of Clinical Oncology; 2016. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V.

Chirgwin, Jacquie H., Giobbie-Hurder, Anita, Forbes, John F., Neven, Patrick, Láng, István, Colleoni, Marco, Thürlimann, Beat, Coates, Alan S., Price, Karen N., Ejlertsen, Bent, Debled, Marc, Gelber, Richard D., Goldhirsch, Aron, Smith, Ian, Rabaglio, Manuela. American Society of Clinical Oncology; 2016. Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence.

Cuzick, Jack, DeCensi, Andrea, Vogel, Victor, Zwierzina, Heinz, Arun, Banu, Brown, Powell H., Castiglione, Monica, Dunn, Barbara, Forbes, John F., Glaus, Agnes, Howell, Anthony, Von Minckwitz , Gunter. The Lancet Publishing Group; 2011. Preventive therapy for breast cancer: a consensus statement.

Stockler, Martin R., Harvey, Vernon J., Gainford, M. Corona, Fong, Akiko, Paksec, Lisa, Sourjina, Tatiana, Zannino, Diana, Gebski, Val, Simes, R. John, Forbes, John F., Coates, Alan S., Francis, Prudence A., Byrne, Michael J., Ackland, Stephen P., Fitzharris, Bernie, Van Hazel , Guy, Wilcken, Nicholas R. C., Grimison, Peter S., Nowak, Anna K.. American Society of Clinical Oncology; 2011. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.

Cuzick, Jack, Sestak, Ivana, Mershon, John, Mitlak, Bruce H., Powles, Trevor, Veronesi, Umberto, Vogel, Victor, Wickerham, D. Lawrence, Bonanni, Bernardo, Costantino, Joseph P., Cummings, Steve, DeCensi, Andrea, Dowsett, Mitch, Forbes, John F., Ford, Leslie, LaCroix, Andrea Z.. Lancet Publishing Group; 2013. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.

The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes, John F.. Elsevier; 2008. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.